Does Blue Cross Blue Shield of Minnesota Cover Jardiance?

What Is Jardiance and Why Do Physicians Prescribe It?

Jardiance is the brand name for empagliflozin, an oral sodium-glucose cotransporter-2 (SGLT2) inhibitor manufactured by Boehringer Ingelheim and Eli Lilly. The FDA first approved it in August 2014 for glycemic control in adults with type 2 diabetes, and three subsequent label expansions have made it one of the most prescribed branded diabetes agents in the United States [1].

The drug works by blocking glucose reabsorption in the proximal tubule of the kidney, causing excess glucose to be excreted in urine. This mechanism produces modest but consistent HbA1c reductions of approximately 0.5% to 0.8% from baseline [2]. More significantly, the cardiovascular and renal benefits that emerged from large outcome trials changed prescribing patterns dramatically.

In the landmark EMPA-REG OUTCOME trial (N=7,020 adults with type 2 diabetes and established cardiovascular disease), empagliflozin reduced the risk of the primary three-point MACE composite (CV death, nonfatal MI, nonfatal stroke) by 14% relative to placebo (hazard ratio 0.86 to 95% CI 0.74, 0.99, P<0.001 for noninferiority; P=0.04 for superiority) [3]. CV death alone fell by 38% relative to placebo. The New England Journal of Medicine published these results in 2015, and they fundamentally shaped how cardiologists and endocrinologists view SGLT2 inhibitors [3].

The EMPEROR-Reduced trial (N=3,730) later confirmed that empagliflozin reduced the composite of CV death or heart-failure hospitalization by 25% in patients with heart failure with reduced ejection fraction (HFrEF), independent of diabetes status [4]. The FDA's 2021 label expansion for HFrEF followed directly from that data [1]. The EMPA-KIDNEY trial (N=6,609) subsequently showed a 28% relative risk reduction in the composite of kidney-disease progression or CV death in patients with CKD, leading to the 2023 CKD approval [5].

These outcomes matter for coverage decisions because payers, including BCBS Minnesota, tie prior authorization criteria to FDA-approved indications. A prescription written specifically for CV risk reduction in a patient with established atherosclerotic cardiovascular disease generally has a stronger authorization pathway than one written for glycemic control alone.

How Blue Cross Blue Shield of Minnesota Structures Its Formulary

BCBS Minnesota operates multiple formulary tiers. Most commercial group plans use a four-tier or five-tier structure. Generic drugs land on Tier 1 (lowest cost). Preferred brand drugs occupy Tier 2 or Tier 3. Non-preferred brand drugs, the tier where Jardiance most commonly sits, appear on Tier 3 or Tier 4. Specialty drugs occupy Tier 5 on five-tier plans [6].

Empagliflozin does not yet have an FDA-approved generic equivalent in the United States as of early 2025, so the brand Jardiance is the only commercially available form. That single fact keeps it in the non-preferred brand tier on most plans, since insurers place drugs on preferred tiers partly to incentivize dispensing lower-cost alternatives. Two generic SGLT2 inhibitors, dapagliflozin (Farxiga has lost exclusivity in some markets) and canagliflozin, may appear as preferred alternatives on certain BCBS MN plans, though formulary status changes annually with each plan year.

The BCBS Minnesota online drug-cost tool (available at bcbsmn.com under "Find a Drug") allows members to search Jardiance by their specific plan name. The tool returns the tier, any restrictions (prior authorization, step therapy, quantity limits), and an estimated cost per fill. Because BCBS Minnesota administers dozens of distinct plan designs for employers across the state, tier placement is not uniform. A member on a small-group plan purchased through the MNsure marketplace may see different cost-sharing than a member enrolled in a large self-insured employer plan administered by BCBS MN.

According to the American Diabetes Association's 2024 Standards of Care, SGLT2 inhibitors with proven cardiovascular benefit are recommended as preferred add-on therapy for patients with type 2 diabetes and established cardiovascular disease or high cardiovascular risk, regardless of HbA1c level [7]. That clinical recommendation carries weight during prior authorization appeals.

Prior Authorization: What BCBS Minnesota Typically Requires

Prior authorization (PA) is the gatekeeper process most members encounter. On the majority of BCBS MN commercial formularies, Jardiance requires PA before the plan will pay any portion of the cost.

Typical PA criteria for Jardiance on BCBS Minnesota plans include:

Diagnosis documentation. The prescriber must confirm a qualifying diagnosis, most commonly type 2 diabetes (ICD-10 E11.x), heart failure with reduced ejection fraction (ICD-10 I50.2x), or chronic kidney disease with proteinuria.

Step therapy. Many plans require documented failure of, or contraindication to, metformin first. Some also require a trial of a generic or preferred-tier SGLT2 alternative. If the patient cannot tolerate those agents due to adverse effects or has a contraindication (e.g., eGFR <30 mL/min/1.73 m² for certain indications), the prescriber can document that as the basis for skipping the step.

Lab values. Plans sometimes require a recent HbA1c (within the past 90 days) or eGFR confirming that empagliflozin is both clinically appropriate and safe.

Prescriber type. Some plans prefer or require that the prescribing provider be an endocrinologist, cardiologist, or nephrologist for non-diabetes indications, though primary care prescribers can typically initiate the process.

The prescriber's office submits the PA through BCBS MN's provider portal or via fax. Standard PA decisions must be issued within 3 business days for non-urgent requests. Under Minnesota state law and federal ACA rules, urgent PA requests require a response within 72 hours.

Approval periods typically run 12 months, after which the PA must be renewed. Renewal approvals are generally smoother if the patient has tolerated the drug and achieved clinical benefit.

What Jardiance Costs With BCBS Minnesota Coverage

Cost-sharing varies considerably depending on whether you have met your deductible, which tier Jardiance sits on in your specific plan, and your plan's copay versus coinsurance structure.

Before deductible: If your plan has a $1,500 or $3,000 deductible and you have not met it, you pay the full negotiated rate for Jardiance, which typically runs $580 to $620 for a 30-day supply at retail pharmacies in Minnesota as of 2024.

After deductible, Tier 3 copay: Many commercial BCBS MN plans charge a flat $50 to $100 copay per 30-day fill for Tier 3 drugs once the deductible is satisfied.

After deductible, Tier 4 coinsurance: If your plan places Jardiance on Tier 4 with 25% to 40% coinsurance and an annual out-of-pocket maximum of $4,000, your per-fill cost could run $145 to $250 until the out-of-pocket maximum is reached.

Mail-order pharmacies designated by BCBS MN (commonly Express Scripts or Prime Therapeutics as the PBM) often provide a 90-day supply at a two-copay rate, which can reduce per-dose cost meaningfully for patients on stable maintenance therapy.

Medicare Advantage members on BCBS MN plans are subject to different cost-sharing structures governed by CMS rules. Under the Inflation Reduction Act, the 2025 Medicare Part D out-of-pocket cap is $2,000 annually, which provides meaningful protection for members needing high-cost branded drugs like Jardiance [8].

Copay Assistance and Patient Support Programs

Even with insurance coverage, Tier 3 or Tier 4 cost-sharing can strain budgets. Several assistance pathways exist.

Boehringer Ingelheim Jardiance Savings Card. Commercially insured patients (not enrolled in Medicare, Medicaid, or any government-funded program) may pay as little as $10 per month for up to 12 months through this manufacturer card. The savings card is available at jardiance.com and can be used at most retail pharmacies alongside BCBS MN coverage. The card typically covers the gap between the plan's cost-sharing and the $10 target.

Boehringer Ingelheim Cares Foundation. Uninsured or underinsured patients who meet income criteria may qualify for free medication through the manufacturer's patient assistance program.

Minnesota Prescription Drug Pricing Transparency Program. Minnesota's Board of Pharmacy operates a drug pricing tool that allows comparison shopping across pharmacies statewide. For some patients, using a cash-pay option (GoodRx, Cost Plus Drugs, or pharmacy discount programs) combined with the manufacturer card may be cheaper than running through insurance if the deductible has not been met.

340B Program Pharmacies. Patients seen at Federally Qualified Health Centers (FQHCs) or certain hospital outpatient clinics in Minnesota may access Jardiance through the federal 340B drug pricing program at significantly reduced cost.

Step Therapy Exceptions and Override Rights

Minnesota enacted step therapy exception rights for insured patients under Minn. Stat. section 62Q.184. Under this statute, a patient or prescriber may request an exception to a step therapy requirement when:

The required first-step drug is contraindicated or would cause an adverse drug interaction. The patient tried the required drug under a previous insurance plan and it was ineffective or caused adverse effects. The required drug is not in the patient's best interest based on sound clinical evidence. The patient is stable on the requested drug (Jardiance) and a step-therapy switch would cause harm.

Exceptions must be submitted in writing with clinical documentation. BCBS MN must respond to step-therapy exception requests within the same PA timelines (3 business days standard, 72 hours urgent).

The American Heart Association and the American College of Cardiology's 2022 guideline on heart failure management specifically states that SGLT2 inhibitors are Class I recommended therapy for patients with HFrEF to reduce hospitalization and mortality [9]. Citing a Class I guideline recommendation is one of the strongest arguments a prescriber can make in a step-therapy override letter.

The Appeals Process If Jardiance Is Denied

A PA denial is not final. BCBS MN members have the right to appeal through an internal review and, if that fails, an external independent review.

Level 1 Internal Appeal. The member or prescriber submits a written appeal with supporting clinical documentation. BCBS MN must issue a decision within 30 days for standard appeals (72 hours for urgent or concurrent review cases). The medical director reviewing the appeal must be a physician with expertise relevant to the condition in question.

Level 2 Internal Appeal. If Level 1 is denied, a second internal review is available. The reviewer must be different from the Level 1 reviewer.

External Independent Review. After exhausting internal appeals, Minnesota members may request an external review by an Independent Review Organization (IRO) certified by the Minnesota Department of Commerce. The IRO's decision is binding on the insurer. IRO success rates for specialty drug denials average approximately 40% to 60% nationally, according to data compiled by the Kaiser Family Foundation [10].

Expedited Appeal. If a delay would seriously jeopardize the patient's health (e.g., a hospitalized patient with HFrEF needing Jardiance before discharge), an expedited appeal compresses the timeline to 72 hours.

Prescribers significantly increase appeal success rates by submitting peer-reviewed literature alongside the clinical summary. The EMPA-REG OUTCOME, EMPEROR-Reduced, and EMPA-KIDNEY trial publications from NEJM are particularly persuasive because they are landmark randomized controlled trials published in top-tier journals and directly cited in major guideline documents [3][4][5].

How a HealthRX Clinical Evaluation Can Support Your Authorization

The HealthRX SGLT2 Coverage Support Framework is a structured intake protocol used by the HealthRX medical team to pre-screen patients seeking empagliflozin prescriptions for insurance coverage readiness. The framework evaluates five elements before the prior authorization is submitted: confirmed qualifying diagnosis with current ICD-10 coding, lab documentation (HbA1c, eGFR, urine albumin-to-creatinine ratio within 90 days), documented trial or contraindication history for required step-therapy agents, cardiovascular and renal risk stratification using validated scores (ASCVD 10-year risk, CKD G and A staging per KDIGO 2024 guidelines), and prescriber specialty designation relevant to the plan's criteria.

When all five elements are documented at submission, the PA is less likely to require supplemental information requests that extend the timeline. For patients whose plans require endocrinology or cardiology sign-off, HealthRX physicians can provide specialist review and co-signature within the telehealth encounter.

Empagliflozin at 10 mg once daily is the standard starting dose for most indications. The 25 mg dose is used for additional glycemic control in type 2 diabetes when tolerated and when eGFR supports it (eGFR should be at least 30 mL/min/1.73 m² for the drug to produce meaningful glucose-lowering, though it retains cardio-renal benefits at lower eGFR values per the 2023 FDA CKD label update) [1].

The FDA's full prescribing information specifies that empagliflozin should not be initiated in patients with eGFR <20 mL/min/1.73 m² [1]. That threshold is a frequent documentation point in PA submissions, because demonstrating that the patient's eGFR is above the minimum threshold removes a common basis for denial.

Alternatives If Coverage Is Denied or Unaffordable

If Jardiance coverage remains out of reach, clinically comparable options exist within the SGLT2 class and adjacent drug classes.

Dapagliflozin (Farxiga). FDA-approved for type 2 diabetes, HFrEF, heart failure with preserved ejection fraction (HFpEF), and CKD. The DAPA-HF trial (N=4,744) showed a 26% relative risk reduction in worsening heart failure or CV death compared to placebo [11]. Dapagliflozin may appear on a preferred tier on BCBS MN formularies and could require less aggressive step therapy.

Canagliflozin (Invokana). FDA-approved for type 2 diabetes and CKD with established cardiovascular disease. The CREDENCE trial (N=4,401) demonstrated a 30% relative risk reduction in the composite renal endpoint [12]. Generic canagliflozin became available in some markets in 2024.

GLP-1 receptor agonists. For patients whose primary goal is cardiovascular risk reduction rather than heart failure or CKD management, semaglutide (Ozempic) demonstrated a 26% relative risk reduction in MACE in SUSTAIN-6 (N=3,297) [13]. GLP-1 agents have distinct coverage pathways and formulary status on BCBS MN plans.

Switching to an alternative because of cost or coverage is a clinical decision that must involve the prescribing physician, particularly for patients with established HFrEF where the SGLT2 class effect appears consistent but individual drug approvals differ.

Minnesota-Specific Regulations That Protect Patients

Minnesota law provides several consumer protections relevant to drug coverage disputes.

The Minnesota No Surprises in Health Care Act requires plans to maintain accurate, up-to-date formulary information on their online drug tools. If a BCBS MN formulary tool showed Jardiance as covered at a specific tier and the pharmacy charged more, the member has grounds to file a complaint with the Minnesota Department of Commerce.

Minnesota Statute 62A.149 governs internal appeals timelines, consistent with ACA requirements. Members who believe BCBS MN violated appeal timelines may file a complaint with the Minnesota Department of Commerce, which enforces state insurance law.

For Medicare Advantage members, the Centers for Medicare and Medicaid Services (CMS) oversees plan compliance. CMS Star Ratings include metrics related to drug coverage appeals handling, which incentivizes Medicare Advantage plans to process appeals correctly [8].

The MNsure marketplace navigator program provides free, certified assistance to individuals navigating insurance coverage issues, including drug coverage disputes. Navigator contacts are available through mn.gov/commerce.

Reading the Explanation of Benefits After a Claim

After a Jardiance claim is adjudicated, BCBS MN sends an Explanation of Benefits (EOB) that shows the pharmacy's billed amount, the plan's negotiated rate, the plan's payment, and the member's cost-share. Three specific fields on the EOB are worth checking.

The "denial reason code" field (if the claim was rejected) tells you whether the denial was for lack of prior authorization, step therapy requirements, or quantity limits. Each denial reason triggers a different correction pathway.

The "benefit applied" field shows whether the deductible was applied, which explains why the cost-share was higher than the listed copay.

The "network status" field confirms whether the dispensing pharmacy is in the BCBS MN network. Out-of-network pharmacies generally do not have negotiated rates and may result in no coverage at all for non-emergency prescriptions.

Patients who receive a denial at the pharmacy counter should ask the pharmacist to print the rejection code before leaving. That code, typically a NCPDP reject code (e.g., 75 for prior authorization required, 76 for plan limitations exceeded), identifies the exact administrative block and guides the next step. The prescribing office needs that code to initiate the correct PA or override process efficiently.